Prothena Announces Leadership Team Updates

Annie Kingston promoted to Chief Strategy Officer, Michael Isaacs promoted to General Counsel and Corporate Secretary

Apr. 13, 2026 at 4:48am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a clean, monochromatic background with a few polished, premium-looking objects arranged elegantly, conceptually representing Prothena's corporate strategy and technology.Prothena's leadership updates signal the company's focus on strategic growth and legal oversight as it advances its pipeline of investigational therapeutics.Santa Clara Today

Prothena Corporation plc, a late-stage clinical biotechnology company, announced updates to its leadership team. Annie Kingston is being promoted to Chief Strategy Officer, and Michael Isaacs is being promoted to General Counsel and Corporate Secretary. Mr. Isaacs will succeed Michael Malecek, who will be departing from Prothena.

Why it matters

These leadership changes at Prothena, a prominent biotechnology company, reflect the company's focus on supporting its partnered clinical programs, investing in its wholly-owned preclinical programs and technology, and exploring research collaborations and licensing partnerships to further drive its mission.

The details

Ms. Kingston will lead the company's growth strategy aimed at driving sustainable value creation, while Mr. Isaacs will be the company's most senior legal officer, overseeing the corporate legal function. Tran Nguyen, who previously served as Chief Financial Officer and Chief Strategy Officer, continues to serve as the company's Chief Financial Officer.

  • The promotion of Ms. Kingston is effective immediately.
  • Mr. Isaacs' promotion will take effect following Mr. Malecek's departure in June.

The players

Prothena Corporation plc

A late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise.

Annie Kingston

Promoted to Chief Strategy Officer at Prothena. She previously served as Vice President, Corporate Strategy and Chief of Staff at the company.

Michael Isaacs

Promoted to General Counsel and Corporate Secretary at Prothena. He previously served as Deputy General Counsel at the company.

Michael Malecek

Departing from his role as General Counsel and Corporate Secretary at Prothena.

Gene Kinney, Ph.D.

President and Chief Executive Officer of Prothena.

Got photos? Submit your photos here. ›

What they’re saying

“Prothena is focused on supporting our partnered clinical programs, investing in our wholly-owned preclinical programs and technology, and exploring research collaborations and licensing partnerships to further drive our mission.”

— Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena

“Having already made significant contributions to the Company, both Annie and Mike are well positioned to step into their expanded roles. I am delighted to continue to work closely with them, our Board, and the rest of the leadership team as we execute our long-term strategy.”

— Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena

The takeaway

These leadership changes at Prothena demonstrate the company's commitment to driving its strategic priorities, including supporting its clinical programs, investing in its technology, and exploring partnerships to further its mission in the biotechnology industry.